Generics Cos. Can't Pare Novartis Patent Infringement Suit

Law360, New York (October 23, 2013, 8:03 PM EDT) -- A New Jersey federal judge on Wednesday denied a bid by Apotex Inc. and other generic-drug makers to trim Novartis Pharmaceuticals Corp.'s suit against them, saying it was too early in the proceeding to determine whether their use of a drug ingredient infringed Novartis' patents.

Novartis has targeted more than a dozen generic-drug makers, including Apotex, Sun Pharmaceutical Industries Ltd. and Wockhardt USA LLC, seeking to block the companies from producing zoledronic acid, the active ingredient in its osteoporosis drug Reclast and oncology drug Zometa. Novartis...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.